AstraZeneca has shunned Pfizer's previous approaches
Media playback is unsupported on your device

Pfizer new 'final' offer rejected by AstraZeneca

UK drugs company AstraZeneca has rejected an improved "final" takeover offer from US drugs giant Pfizer.

Pfizer had made a new offer of £55 per share, valuing AstraZeneca at about £69bn.

But AstraZeneca says the new proposal "undervalues the company and its attractive prospects".

Kamal Ahmed reports.

Go to next video: Political week in 60 seconds